Apr 12, 2010 - Allowance Broadens Portfolio for the Treatment of Obesity and Related Diseases - MDRNA, Inc. (NASDAQ: MRNA), a leading RNA interference (RNAi)-based drug discovery and development company, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/234,547 covering formulations for the intranasal delivery of Y2 receptor selective agonists.Y2-receptor agonists are a family of peptides (pancreatic polypeptide, peptide YY, and neuropeptide Y) that play a central role in caloric intake. The natural release of these peptides in association with meals directly influences how efficient and effective the body utilizes sugars, carbohydrates and other nutrients. Y2-receptor agonists can regulate food intake at the level of the brain, pancreas, and intestinal tract, and may provide treatment to prevent overeating and excessive weight gain, and the numerous adverse health effects associated with obesity.
"MDRNA's focus remains the development of therapeutic products based on RNAi, however we believe that our legacy nasal assets have significant value,"... MDRNA's Press Release -
